• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The novel compounds of the formula (I) <IMAGE> in which the substituents are defined in Claim 1, are obtained by fermenting a C-076-producing strain of Streptomyces avermitilis in an aqueous nutrient medium containing an assimilable source of carbon, an assimilable nitrogen source and inorganic salts under aerobic conditions and isolating C-076 from the fermentation broth. The novel compounds can be used as active components in pesticidal compositions and also for the prophylaxis and treatment of parasitic diseases.
    公开号:SU716524A3
    申请号:SU772474802
    申请日:1977-04-18
    公开日:1980-02-15
    发明作者:Алберс Шонберг Георг；Уильям Бэрг Ричард；Уильям Миллер Томас；Юджин Ормонд Роберт；Воллик Химан
    申请人:Мерк Энд Ко, Инк. (Фирма)；
    IPC主号:
    专利说明:

    (54) METHOD FOR OBTAINING SUBSTANCES OWNING ANTIPARASITIC ACTIVITY
    NRRZ 8165. A sample of NRRZ 8165 was also deposited in the permanent collection of the American Type Culture Collection in Parklaun Drive Maryland 20852 and received the serial number ATCN 31, 267.
    Morphological and cultural characteristics of the following. The morphologist sporophores form spirals in the form of the lateral branches of the aerial mycelium. The spirals are compact, but are made more open as the culture ages. Spore-chains in no more than 15 spores, usually have a spherical or oval shape (with an increase of 970 times). Spore formation is observed in agaic with oatmeal, coca, glycerol-asparagine, salts, starch and egg albumin. The surface of the dispute is smooth. Agar with oat flour; the reverse side is dark brown. Aerial mycelium: powdered brownish-gray (41), (projection of numbers, colors taken from Co2pr Hermany Mite, 1b5v / 1-th tdftion Conteiner ot AgpeNsd, Chlcogo, OU. Mixed with white. Soluble pigment; brown Lapek DoCe agar (sucrose nitrate). Vegetative growth; poor,
    colorless.
    Aerial mycelium scanty
    grayish.
    Soluble pigment; grayish brown light tone. Egg albumin agar: moderate vegetative growth, light grayish-yellowish-brown (VGG mixed with white.
    Soluble pigment: light server-brown.
    Glycerin-aspartic agar, vegetative growth; the reverse side is yellowish brown. ,
    Air miel; powdered brownish gray (411) mixed about white.
    Soluble pigment: light, yellowish brown.
    Inorganic salts - starch.
    Vegetative growth: the reverse side is grayish-yellowish-brown.
    Aerial mycelium: powder, light, brownish-gray (411) along the edges and darker brownish gray (4li}.
    Soluble pigment: light yellowish brown.
    Agar with yeast extract-dextro-salt.
    Vegetative growth: the reverse side is dark brown.
    Aerial mycelium: moderate, brownish-white.
    Soluble pigment: brown Agar with pento-iron-yeast extract.
    Vegetative growth; dark brown .
    Aerial mycelium: no.
    Soluble pigment; from dark brown to black.
    Milanin: Positive reaction.
    The selection is positive.
    0
    Yeast Maltextract Agar.
    Vegetative growth: the reverse side is dark brown.
    Aerial mycelium: moderate,
    5 brownish white.
    Soluble pigment; brown. Nutritional aga.
    Vegetative growth: brown.
    Aerial mycelium: scanty, 0 grayish.
    Soluble pigment; light brown ..
    Nutritional starch agar. .
    Vegetative growth: brown. 5Air mycelium; scanty, grayish-white.
    Soluble pigment; light brown .
    0Hydrolysis of starch; good.
    Potato mass.
    Vegetative growth: brown.
    Air yetzelium: brown, mixed with grayish-white. 5 Serum blood Leflera.
    Vegetative growth: grayish brown.
    Aerial mycelium: no.
    Soluble pigment: some, darkening of the medium.
    0
    Thinning: no. Nutrient tyrosine agar.
    Vegetative growth: - the reverse side from dark brown to black.
    5Air mycelium: poor,
    grayish.
    Soluble pigment: dark brown.
    Decomposition of tyrosine; not. Q Digestion - carbon.
    The main environment Pridgem Gottlieb 1 1% carbon source -f (+ growth, no growth, compared to the control without a carbon source).
    five
    Glucose + manniton +
    Arabinose + mannose +
    Pulp - FaLinoza + Fructose + Rhamnose +
    Lactose + sucrose +
    0 Maltose + xylose +
    Inositol + Nutrient Gelatin Agar.
    Vegetative growth: KopHiHeBFjA.
    Aerial mycelium: poor, 5 grayish-white. Soluble pigment: light pink. Dilution of gelatin: good, Gelatin (inoculation by injection). Vegetative growth: brown ring. Aerial mycelium: no. Soluble pigment: greenish brown, Liquefaction of gelatin: complete. Agar-skimmed milk. Vegetative growth: dark brown. Aerial mycelium: no. Soluble pigment: dark brown. Casein hydrolysis: good. Litmus milk. Vegetative growth: dark brown growth ring. Aerial mycelium: no. Color - dark brown. Coagulation and / or peptonization: complete, made alkaline (pH 8.1 Unnumbered milk. Vegetative growth: dark brown growth ring. Aerial mycelium: no. Soluble pigment: dark brown. Coagulation and / or peptonization: full of peptonization, it is made alkaline (pH 8). Temperature: (yeast tract agar + salt): - good vegetative growth and aerial mycelium, - good vegetative growth; and aerial mycelium, - no growth. Oxygen demand: ( cult injection in agar with a yeast extract + salts). Aerobic culture. All definitions were made after three weeks, unless otherwise specified. The pH values of all media are almost neutral (6.8-7 Comparison of these data with published descriptions, including the Guide to Certain Berke Bacteriology (8 editions of known microorganisms, significant the differences indicate that this microorganism must be classified as a species. On this basis, it was called Streptomvces C (vermUi is. C-076-compound is obtained by fermentation of a suitable water nutrient medium strain of Streptomvces c in the conditions described below The media used to produce many antibiotics are also suitable for this C-076 compound production process. Such nutrient media containing sources of carbon and nitrogen assimilated by microorganisms and a small amount of inorganic salts. In addition, fermentation media may contain traces of metals necessary for the growth of the microorganism. They are usually present as complex compounds of carbon and nitrogen sources, using ix as a power source, but they can be added to the medium separately. Carbohydrates such as sugars, such as dextrose, sucrose, maltose, lactose, dextran, cerelose, and the like. and starches are good sources of assimilated microorganism carbon in nutrient media. The amount of carbon source used in the medium depends in part on the amounts of the other components of the medium and is usually 0.5-5% by weight of the amount of the medium and is considered sufficient. Carbon sources can be used separately, or they can be combined in media with other components. In the formation of C-076 compounds easily assimilated by the 5trep omvces civermitiPis strain, various nitrogen sources are used, such as yeast hydrolysates, yeast autolysates, soybean flour, casein hydrolyzates, yeast extracts, corn starch liquids, corn bard, cotton flour , mnye extracts, etc. Either one source, nitrogen, or in combination with other compounds in an amount of 0.2-6 wt.% Of the medium can be used. Among the nutrient inorganic salts that can be introduced into the culture media, are the usual salts capable of producing ions of nati, potassium, magnesium, ammonium, calcium, phosphate, sulfate, chloride, carbonate, etc. Ice of metals such as cobalt, arganese, iron, etc., is also introduced into the pool. Next, examples of media were obtained, according to the invention, of growing strains of Siceptomvces ovcrmitiPis strains in order to obtain C-P76. Connections Wednesday A. Maize flour, g20.0 Soev flour, g15.0 Barda, g10.0 Sodium citrate, g4.0. , g0,5 Polyglycol P 2000, ml2.5, g0.1 SaC12bN „0, g0.01 FeSO. , g0.01 Distilled water, ml pH 6.51000 Medium S Soluble starch, g20.0 CHicide from maize locking, g15.0 Pereloza, g5.0 Soybean flour, g4.0 (NH) SO, g4.0 Maize flour, g1.0 Soybean oil, ml2., 5 KN PO, g0.3 CaCOj, g6.0 Distilled water, mlnH6.71000 Medium C Tomato paste, g40.0 Ova per flour, g15.0 Distilled water, ml pH 6.01000 Oats for flour, r20., 0 Tomato paste., G20.0 Distilled water, ml pH 5.5 .1000 Medium E Dextrose, g10.0 Peptone (DILko Laboratories of Detroit), 5.0 g Yeast autolysate, g 3,0 (Ardamine ON Lirma East Products Inc., Paterson) NaCJ, KSO, g 0.72 FeSO (SO 6H, O. 0.035 MdS1g-bNg.O / g5.32 CaC2. 2 H, 0, gO / 73 Distilled water, ml pH 7.41000 Fermentation with the use of micro-organisms forming C-07b-compound can be carried out at 20-40 С Dp obtaining optimal results, it is most expedient to carry out these fermentations at temperatures of 2–4–30 ° C. Temperatures of 27–28 ° C are most preferable. 6.0-7.5. Fermentation in small quantities is conveniently carried out in a flask under sterile conditions, contaminating the nutrient medium with spores or vegetative cells of the Slt-eptomvces av miWis strain forming C-076-compound. The flask is capped with cotton and kept at a constant temperature and shaken for 3-10 days. When working with large quantities, fermentation is recommended to be carried out in a vessel equipped with an agitator and in order to aerate the nutrient medium. The nutrient medium is prepared in a vessel, sterilized, and then charged with a source of vegetative cell material of the strain Strepto ces Qvermitieis, forming its C-0 compound. Fermentation is continued for 1-8 days with stirring and / or aeration of the nutrient medium at a temperature of 24-37 ° C, stirring speed of 95-125 rpm and with air supply 1.8-18. The new substances obtained according to the invention, referred to herein as C-076 travel, are at the end of fermentation mainly in the mycelium and can be extracted and separated as described above. Four major and four minor components of the C-07b-compound, formed by Streptomvces overmUieis, were identified. Eight different compounds of C-076, Ala, A1b, A2a, A2b, B2a, B2b, te2a, B2b were identified. The main components are labeled 1 letter, a minor letter in. The structural differences between quince joints should be the same for each of the four pairs. As would be expected, even the major C-076 compounds are not formed in equal amounts under the fermentation conditions described here. So, A1 compounds make up 20-30 wt.% From the total amount of the resulting complex C-076, compounds A2 make up 1-20 wt.% - compounds B1 and B2 each 25-35%. The weight ratio of p das compounds to a series of compounds is 85-15 - 99: 1. Separation of compounds C-076 from the entire fermentation mass and extraction of individual components. produced by solvent extraction and chromatographic fractionation using various chromatographic methods and with various solvent systems. C-076 compounds are poorly soluble in water and well in organic solvents. This property is used to extract them from the fermentation medium. Thus, in one extraction method, the entire fermentation mass is filtered and the aqueous filtrate is discarded. The pressed wet filter residue is then extracted into the mycelium with a suitable solvent. Although any organic solvent can be used, it is better to use a solvent that is miscible with water, for example acetone, methanol, ethanol, etc. To achieve maximum recovery, multiple extraction is recommended. The solvent extracts the active ingredients C-076, as well as the substances that do not possess the anti-parasitic activity of compound C-076. If the solvent is mixed with water, then the water is also removed from the wet mycelium. Extracted mycelium can be discarded. Evaporation extracts to remove the organic solvent and extraction are repeated several times with another solvent. If a
    in the first extraction, applied. cM5 water-soluble solvent, it is preferable to use a solvent that is not miscible with water, for example chloroform, methylene chloride, carbon tetrachloride, ethyl acetate, methyl ethyl ketone, methyliso (; ethyl ketone, etc., the resulting extracts are dried and concentrated by conventional methods. residues containing G-076 compounds with impurities of other compounds. Then this fraction is chromatographed to separate the active C-07b compounds from other material and also to separate the individual C-076 compounds. d. The residue is chromatographed on a column using such media as silica gel, aluminum oxide, dextran gels and the like and derivatives elution or different solvents and / or a combination of two or more solvents
    taken in various ratios. liquid chromatography is used to open C-07H compounds and high pressure liquid chromatography can be used to isolate purified fractions containing one or more compounds. Similarly, thin-layer imaging can be used to detect and isolate individual C-0 76 compounds. The presence of active C-076 compounds
    0 is determined by testing various chromatographic fractions for antiparasitic activity and also by the spectral characteristics of these compounds.
    five
    The spectral and other physicochemical characteristics of the individual G-076 median are given in Table 1. These compounds are readily soluble in most; common organic solvents and have minimal solubility in water,
    table i
    Molecular, О, with N. О formula +48, 8 ° ± 2 ° Optical +68,5 ± 2 rotation {d} () (, 77)
    Molecular weight
    (determined by mass spectrometry) .886
    Ultraviolet spectral data was obtained using a Keri ultraviolet spectrometer, model 15 in methanol solutions in quartz cells, 1 cm in area. Although ultraviolet absorption is presented as absorption of a series, it actually represents absorption of compounds of a series containing (, 64 )
    876
    890
    858
    872
    impurities of compounds of the series c. Rows a and b differ only in the number of -CH c. a low alkyl substituent and this 60 nd difference is not associated with the chromophore. Ultraviolet absorption primarily characterizes the degree and nature of the unsaturated network in the compound; Optical problems are determined by the standard methods and the field C, H, H O, C H,, H. CdtHyO ,; + 55. ° ± 2 .. + 38 ,. (, 06) (, 87)
    11716524. 12
    Geyss's meter. The concentration factor applied to tetramethylsilane in ka (c) is given as the amount of the compound of the internal standard. Volume
    neither in a given solvent, expressed-solution or sample concentration
    new in percent .. are indicated in each case with the subsequent 13C NMR spectrum for C-076 5 but tetramethylsilane for each soyA1a, A2a: BiaA and B2b are given in table 2. denini, given in parts per million. Spectra obtained using spectro-chemical shifts are given for an individual nuclear magnetic resonance carbon atom, if not stipulated. Option СЕТ-20 in deuterated otherwise, in brackets after the chemical chloroform solvent at. Q, 11,612,413,815,1 .17,7
    Chemical shifts relative to Table 218, 4, 19,920,227.3 Characteristics of the mass spectral peaks of eight C-076 lead compounds, table 3. The first line of the table (5 faces shows the ratio of mass to 1 for | 5 dU. (M / e) of the molecular ion, each corresponding compound, and the remaining figures give the ratio of the mass to the charge of the main fragments of each compound. The ratio of the masses to the charge in one horizontal row indicates similar fragments; YOU of each compound. Based on the experimental data, studies and measurements described here, it is considered that; С-П76-compounds must have the following structural formula: R-0 LLJ
    Continuation of the table, 2. (Ls where R is a y-olendrozil-JT -1-oleandroside of the structure Hz BUT and where the dotted line indicates a single or double bond; R is a hydroxy group that is present only when the dotted line indicates a simple bond b, R is butyl or propyl, and R is a methoxy or hydroxy group. The individual compounds that make up this structural Lormula are inferior to: 15 Compounds in which Rj-butyl (compounds of row a) and the corresponding compounds of which P. propyl (compounds of a number in a) behave the same in most extraction processes, for example measures during solvent extraction, in each pair of compounds a and in compound a are in larger quantities and usually comprise 85-99% of the mixture of compounds a-and V. The presence of propyl compounds is confirmed by the mass spectra of the compounds where the peaks are Fragments containing the butyl group, have pair peaks with a mass of 14 units (or one -CHj) less. In addition, it should be noted that high-pressure liquid chromatography was used to separate the components B1b from the Ala components and the mass spectrum of such A1b-co-dinechi confirmed High resolution mass spectra was given (see table 3): The new compounds obtained according to the invention have significant parasiticidal activity, such as antigel, insecticide and acaricides, in animals and in agriculture. As finished preparations, these compounds can be administered orally , for example, in the form of capsules of large pills or tablets in the form of liquid, plentiful doses of anthelminths for mammals. Such individual doses can vary widely in the total weight and content of the antiparasitic agent, depending on such factors as the parasite to be destroyed, the strength and type of infection, and the weight of the animal. The proposed compounds can be used either as purified individual C-076 components, or as impurities of two or three individual components, therefore it is not necessary to carefully separate the various C-076 compounds obtained after purification of the fermentation medium. Typically, a mixture containing two or more C-076 compounds, but no other compounds, is used to prevent parasitic diseases. Such a mixture usually contains C-07b compounds in arbitrary ratios, but they all have significant activity. Antiparasitic activity can be accurately determined. In particular, it is not necessary to separate the components in from the related component in. Such compounds differ only in the length of the 25th side chain. The separation of such related compounds is not done orychno, since the compounding is present only as an impurity. C-076 compounds, when added to animal feed, can be used as mycelium cake of the Leam introduction medium. Since the mycelium is sufficiently active and the activity level of the mycelium can be determined, it can be added directly to the animal feed, Example 1, Wednesday 1 Tomato paste 20 g / l Yeast 10 g / l Modified starch, Sod, a. g / l Polyglycol 20000,321 mp / l Distilled Enough pH 7.2-7.4 times the amount of the Stage. A. 50 MJI Medium 1, labeled in a 250 ml Erlenmeyer flask, is inoculated with a Streptomvces overmitiPis MA 4680 frozen ampoule. The flask is incubated while rotating the shaker at a speed of 160 rpm in a circle of 50 mm in diameter for 24 hours. Stage B. 500 ml medium 1, contained in an Erlenmeyer flask, is inoculated with 10 ml of flask content of step A. A. The medium is incubated while rotating the shaker at a speed of 150 rpm in a circle with a diameter of 50 mm for 24 hours. Stage C. In 189 stainless steel fermentation tank l pour 160 l of medium 2 and add 500 ml ml The material obtained in stage B. Chan is incubated at 28 ° C with a stirrer rotating at a speed of 150 rpm for 24 and a speed of aeration of 2.7 m / min. Medium 2. Dextrose, g / l 1 Corn starch, 10 g / l Meat extract, g / l Autolyzed yeast, g / l MgSO-7H2O, g / l. 0.05 g / l O, 10, O, 182 Sufficient Distilled water pH 7.0-7.2 quantity. Step D. 457 liters of medium 6 are poured into a stainless steel fermentation tank with a capacity of 756 liters and 43 liters of the grafting material obtained according to stage C are added. The tub is incubated at 28 ° C with stirring and the rotation speed of the stirrer is 114 rpm air flow 9. Stage 3. Selling starch, CPC, g Modified (CPC Corp. firms, 40.0 Barda grams, g7.0 A B eto ziro into enny yeast (Ist5,0 products Inc.), g CoCijj-SHjO, mg50 Distilled 1000 water , ml pH 7.3 Stage E. At the end of this, the whole culture medium is filtered and the compounds containing C-0 compounds left on the filter are washed with water. Then it is stirred up in 120 l of acetone for 30 minutes, filtered and washed 30 l of acetone. Acetone extracts are combined and evaporated: under reduced pressure to a volume of 40 l. Diluted hydrochloric acid pH of concentrate d t to 4.0. The concentrate is extracted 3 times with arbitrary amounts of chloroform. Chloroform extracts are dried by passing through a layer of infusor earth (Sap Cel). The combined extracts are concentrated under reduced pressure to 4 L. Chloroform concentrate is rubbed and loaded into a column filled with 2 , 9 kg of silica gel in chloroform, column is eluted with chloroform, collecting eight fractions of 3.5 l each, then the column is elgated with mixture; chloroform: methanol- (49: 1), eight more fractions of 3.5 l each; (Fractions 9-16). Fraction 3 was evaporated to dosage and 76 g of oily Bee were obtained, containing mainly C-076 compounds. 97% of this product is dissolved in 685 ml of methylene chloride and chromatographed on 600 g of silicic acid. The column (diameter 7.3 mm, length 36 cm) shows 7.5 l of a mixture of methylene chloride and benzene (7: 3) and then 2.26 l of a mixture of methylene chloride benzene-7: 3 with the addition of 5% isopropanol. The fraction eluted with chlorine, methylene, and benzene with the addition of 5 isopropanol has a clearly colored band and contains virtually all C-076 material, as determined by thin layer chromatography (see example 5). This fraction (500 ml) is evaporated and again chromatographed on 105 g of silicic acid (column diameter 3.7 cm, length 18 cm) in methylene chloride. The column is developed in three portions of methylene chloride, 100 ml each, containing 4.10 and 20% ether. Further elution with chloride / 1 methylene with a content of 20% ether gives 2 stained bands. The fraction between the two bands actually contains all the C 076 material, as determined by chromatography in the trading layer. The fraction, which is C-076, is chromatographed on 59 g of co-necic acid 1 (3.7 cm column diameter, 11 cm length in methylene chloride .. The column is washed with methylene chloride containing 10% ether. At the beginning of the eluted, 70 ml fractions are taken and then taken 26 fractions of 5-6 ml each. Fractions 3-26 are combined and 1.35 g of material is obtained, it is analyzed by chromatography in a thin layer (silica gel plates Antac GF 254, produced by methylene chloride containing 5% isopropanol. A substance having Rf 0 , 28 is C-076 A1.: The column is eluted with methylene chloride containing 20% ether (200 ml), then methylene chloride containing 50% ether (800 ml. Get a small amount of a mixture of C-076 A1 and A2 and the rest of the amount of C-076 A2. Weight C-076 A2 800 mg. When 135 mg of C-076 B1 is obtained by further elution with methylene chloride containing 5% isopropanol. Separation is effected by ultraviolet absorption of the eluate. C-07P B1 and A.2 have very close Rf values on silica gel plates in a thin layer (tg) GF 254) and methylene chloride with 5% isopropanol. However, both components are clearly distinguished on the same plates produced by hexane containing 10% isopropanol. The whole C-076 A1 fraction was applied to 14 silica gel plates (antac CF 254, 20 x 20 cm, thickness 500 µm). The plates exhibit hexane with 10% isopropanol. The strip containing C-076 A1 is removed from the plates, extracted with ether and reapplied to 6 plates and 5 times developed with hexane containing 5% isopropanol. C-076 A1 is removed from the plates, chromatographed again, developed with pure ether, and 270 mg of almost pure C-076 A1 are obtained. The IR and NM spectra of this sample are listed in Table 2. Fraction C-076 A2 was chromatographed on 10 silica gel plates (analtac HF 254), developed 5 times with hexane containing 15% isopropanol and 265 mg of almost pure C-076 A2 were obtained, and the IR and NMR spectra of the sample of this substance are given in table. .2. The C-076 B1 fraction is chromatographed on 2 silica gel plates (as shown above) with hexane containing 15% isopropanol and 55 ml of almost pure C-076 B1 are obtained. The NMR spectrum of that sample is given in that “l, 2. Example 2. The fermentation described in Example 1 is repeated twice and both media combined. The fermentation medium is treated in the following way, as in Example 2, to obtain 3.3 liters of the initial chlorprophoric extract, which contains 60 mg / l of all substances and according to data chromatography in a thin layer of O, T, -Co1-L; + Yeni {C-076.
    3 l of this chloroform solution is chromatographed on 2400 g of silica gel (Davidson, grade 62) in chloroform. The column (.9.5x122 cm) is developed in eight portions of 3800 ml of chloroform (fractions 1-3), then in eight portions of 3800 ml of a mixture of chloroform: methanol-49: 1 (fraction 9-16). Individual fractions are analyzed by chromatography in a thin layer (silica gel plates Quant / Gram 01G), produced by chloroform: methanolomes el9: l. Each of fractions 9-11, 12-13 and 14 is evaporated to dryness, and 6.63 g of solids containing components C-076A are obtained, in fractions 9-11, 24.9 g of solids containing components C-076B, fractions 2-13 and 4.7 g of solids containing C-07bB components in fraction 14.
    Fractions 12-14 are combined (29.62g), dissolved in 100 ml of methylene chloride, and chromatographed over 400 g of silica gel (Davidson, grade 62) in methylene chloride. The column was eluted with iSOQ ml of a mixture of methylene chloride: 2-propanol-99: 1, 1500 ml of a mixture of methylene chloride: 2-propanol-49: 1, 2000 ml of a mixture of methylene chloride :. 2-propanol-19: 1 and 1000 ml of a mixture of methylene chloride: 2-propane-9: 1. 2.56 g of a substance isolated from a 5500 ml eluate and 5.09 g isolated from an elute; volume of 60006500 ml, dissolved in 25 ml of methylene chloride and chromatographed over 60 g of silica gel in hexane. The head fractions were collected from 70 ml of hexane and 100 ml of diethyl ether mixture 4: 1 and then the column was developed with 600 ml of a mixture of hexane: diethyl,. take 20 ml fractions and then elute 700 ml of ether and select 100 ml fractions. From eluates with a volume of 400,600 MP, 1.035 g of solids are obtained, containing C-076 components B1; from volumes. 600-1000 ml receive 0.881 g of solids containing ... See components B1, B2 0-076, and from volumes 1100-1500 ml receive 0.381 g of solids containing B2 components C-076.
    The mixture of components B1 and B2 is then dissolved in 4.2 ml of a mixture of methanol: and chromatographed on Poril C18 (Bondanac 37-75 µm in the same solvent. From the reverse phase high pressure column (first more polar components are eluted) 1.2 m x 16 mm elute the substance at a rate of 800 ml / h and select fractions of 21.3 ml each. The presence of components C-076 is confirmed by observing the UV absorption of the fractions. C-076 B2 weighing 137 mg is recovered in fractions 24-37 and C-076 B1 weighing 195.4 g in fractions 51-70. Then each sample is separately chromatographed on columns, filled 4 g of silica gel (Devilson, grade 62) in methylene chloride. The columns are eluted with 35 ml of methylene chloride: methanol 9: 1. The last 20 ml of eluate from each column is collected, evaporated to dryness and receive 155.8 mg of C-076 82 and 90 mg C-076 B1.
    Then, 50 ml of C-076 B1 and 100 ml of C-076 B2 are chromatographed on preparative silica gel plates.
    (Antac HF 254) is extracted with hexane containing 12% isopropanol, followed by extraction with ether and almost pure C-076 B1 and C-076 B2 are obtained. Example 3. 50 ml of medium
    located in an Erlenmeyer flask with a capacity of 25 ml, composition, wt.%:
    Lactose2,0
    Barda.1,5
    Autolyzed 0.5
    0 yeast
    The pH before sterilization of 7.0 was inoculated with the contents of a frozen ampule of Streptomvces avermiti is MA 4848 and incubated in a 5 rotating shaker at 28 s for 24 hours at a speed of 150 rpm.
    . 10 ml of this fermentation medium is used to inoculate the same 0 medium in a two-liter Erlenmeyer flask. The fermentation medium was incubated at 24 hr at 50 rpm in a rotatable agitator.
    All of these media are then used for
    inoculating 467 l soyedy in a fermentation tank with a capacity of 756 l of the composition, weight,%: Lactose 2.0
    Bard .1,5
    Autolyzed 0.5
    yeast
    Polyglycol 2000 ml, l. 0.32 pH before sterilization 7.0 The fermentation medium is incubated at 40 hours by passing air 5 (9 mE / min) with stirring at 130 rpm.
    230 l of this medium is used to inoculate those in a stainless steel fermentation tank with a capacity of 5760 l of medium of the following composition,
    weight.%:
    Dextrose 4.5, Peptonized Milk.
    f Autolized
    yeast0.25
    Polyglycol, ml / l 2.5 pH before sterilization 7.0 Fermentation is continued for 144 hours at 26 ° C by passing air 60 49 and stirring with a rotation speed of the stirrer 120 rpm.
    The fermentation medium is filtered off, the filter cake is mycelium. The mixture is washed with 550 l of water and the filtrate and $ 5; the washing water is discarded, the filter cake is stirred up for 1 hour with 500 l of acetone and filtered. The filtered cake is dried with 150 l of acetone and 40 l of water and about 2000 l of extract is obtained. Fermentation and extraction are repeated in the same quantities and another 2000 liters of acetone extract is obtained, which is then combined with the first extract and evaporated to 800 liters with concentrated hydrochloric acid; The pH of the concentrate is adjusted to 4.7 and 800 L of methylene chloride is added. The combined solvents are stirred for 4 hours and the layers are separated. Another 600 liters of methylene chloride is added to the aqueous layer and stirred for 4 hours. The layers are separated and each extract is separately treated. Both extracts are evaporated to a total volume of 60 l. Example 4. 60 l of the solution from the previous example are evaporated to dryness in vacuo to remove residual methylene chloride and 60 l of methanol are added to the residue 3 times. The final volume of methanol concentrate is 36 l. The methanol solution is exhausted overnight and filtered. The filter cake is washed with 40 liters of fresh methanol and the filtrates and washings are combined. Then 95 liters of ethylene glycol and 130 liters of heptane are added to the methanol solution. The bilayer solution is washed with a mixture of 20 liters of ethylene glycol and 6.3 liters of methanol. After 5 minutes after mixing, the lower layer is: divided and combined with the first ethylene glycol-methanol extract. An equal volume of water (about 150 liters) containing 79 g of salt per liter is added to this extract. The resulting solution was extracted with 150 L of ether and stirred for 5 minutes. The ether layer is washed with 75 liters of water. (1/2 volume), mix for 5 minutes and separate the layers. This process is repeated 2 more times (npONHBHafl water contains 20 g of salt per liter). The ether layer is evaporated in vacuo to a mini volume at a temperature of less than. 40 liters of methylene chloride are added to the residue and the solution is evaporated to dryness. This process is repeated and the final residue is concentrated in vacuo to dryness. Example 5. A layer of 34 kg of activated alumina and then a layer of 34 kg of activated carbon in methylene chloride are loaded into a column with a diameter of 20 cm. The residue from the previous example is dissolved in methylene chloride to a volume of 34 liters, poured onto a column and 34 liters of methylene chloride are eluted and these fractions are discarded. A 3% solution of isopropanol in methylene chloride (20.8 l of isopropanol and 660 l of methylene chloride) is fed into the column and eluted, and a fraction of 200 l is selected. These fractions are evaporated in a vacuum in a bath heated to a volume of 20 liters. Then reduce the bath temperature to 45 ° C, the extract is evaporated in vacuo to dryness. The residue is dissolved in 10 hours of methylene chloride, 10 hours of hexane and 1 hour of methanol to a final volume of 15 liters. This solution is loaded directly onto a Sephadex H-20 column. Example 6. A column with a diameter of 30 cm is loaded with 36. kg of Sephadex H-20 and washed with a mixture of methylene chloride: hexane: methanol: 10: 1. 0.25 C-076 solution is poured into the column and eluted at a rate of 250 ml / min. The first two fractions of 20 l are selected, which are discarded, and then the 20 fractions of 20 l each. The last fraction is also discarded. It has been found that fractions 1-8 contain C-076-compounds A- and fractions 9-10 B-compounds. 680 g of this sample is dissolved in 2 liters of methylene chloride, loaded into a 22-liter three-necked round-bottom flask, and 13.6 l of methanol is added. Then methylene chloride is distilled off in vacuum, simultaneously dbbavl 13.6 l of ethyl acetate. The rate of distillation is adjusted so that the temperature of the solution was not lower than 65. ° C. After addition of ethyl acetate, the solution is cooled at -16 h. The crystals are filtered and washed with 1 l of cold ethyl glycol. The crystals are then redissolved in 2 liters of methyl chloride. and the solution is loaded into a 22-liter three-necked round-bottom flask. This procedure is repeated twice. For the first time, 12.5 liters of methanol and ethylene glycol are used for the first time and 13.5 liters for the second time. The crystals obtained at the end are washed with 1 l of cold ethylene glycol and 1 l of water. The crystals are dissolved in 4 liters of water and dried by filtration over sodium sulfate. The benzene solution is concentrated to 2 liters, lyophilized, and 341.2 g of a white powder is obtained consisting of 98% C-076-B1 and 1% C-076-B2. The stock solutions after β-crystallization are combined and diluted with 22. l of water. The aqueous solution is extracted with 60 liters of toluene and again, 15 liters of toluene. The toluene extract is then washed with 48 liters of water. The organic phase is filtered to remove residual water, evaporated to obtain 336 g of solid material consisting of 79% from -076-B2 and 16% from 0-07 B1 compounds. Example 7. In four of the columns filled with Sephadex U. K-20, as in Example 6, Fractions -8 are obtained and combined. According to the data obtained using high pressure liquid chromatography, it was found that the mixture contains 252 g C-076 A2a, 16 g A2B, 94 g Ala and 24 g A1b. The resulting product is dissolved in a solvent mixture of hexane toluene: methanol - 6: 1: 1 and loaded into a column with Sephadex H-20 of the same size as in Example 2. The fraction is collected at an elution rate of 250 ml / min, the first 20 liters being discarded. Then, another two 20-liter primary fractions are obtained by elution, which also discards 50 fractions of 4 liters each, which contain the C: 07b A compound. It was found that | Fractions 3–8 contain predominantly; the A1 components (g Ala and 6.7 g A1b) and fractions 29-36 C-076 A2 of the compound (117.2 g A2a and 7.35 g A2b). The fractions contained a mixture of C-076, A1 and L2 compounds. Example 8. Sample C-076: B1 from example 7 weighing 150 g is dissolved in 3 l of a mixture of hexane: toluene; methanol: 3: 1. The solution is passed through a Sephadex X H-20 column ((of the same size as in Example 6) and fractions are taken at a rate of 250 ml / min. The first two 2-liter fractions are removed and discarded. The head fraction of 10 liters is also discarded. Then 30 rich fractions with a volume of 2 l are collected. Fractions 1-13./I 2.5-30 are discarded. Fractions 14-16 are combined. They are holding 80 g of the preimus natural C-076H1c. Fractions 22-24 are combined. They contain 6.7 d mainly C-076 Harschteristics of m. B1 c. Fractions 17-21 contain a mixture of C-076 B1a and B1c. Fractions 17-21 are combined, concentrated and passed through the column filled with Sephadex LN-20, using the same solvent. The first three fractions of 20 l are discarded. Then the following rich fractions are selected: 5 fractions of 2. l each (fractions 1-5) 20 fractions of 1 l each (fractions 6- 25) and 10 fractions of 2 l each (fractions 26-35) .. Fractions 1-5 are discarded. Fractions 16-21 contain 13.5 g C-G76 B1 and 0.4 g C-076 B2, fractions 22-26 contain 44 g C-076 B1a and 0.13 B1b, fractions 27-30 contain 10.2 g B1b and 0.8 C-076 B1b. The separation of components in from component a is carried out using high pressure liquid chromatography. 30 µl of a mixture of C-076 B1a and A1b in absolute methanol containing 30 µl of C-076 A1b is loaded onto a high pressure liquid chromatography column containing Sphery-Sorb 5 µm OD8 (Spectrum Physics) as a nozzle. The column was eluted with methanol: water 85:15 at a rate of 15 ml / min. The elution is monitored by the UV absorbance of the eluate and the individual components are collected at the exit of the UV instrument. Remove 30 μg C-076 and analyze in a mass spectrometer. The mass spectrum of this sample is given in the second column ab.3. Tables 4 and 5 show the antiparasitic activity of the compounds obtained. Ectral pmkov T a b l and c a
    Type of organism Treatment was not produced 70 .442-1,421 dili 1.-676, 895,) (-OOP07 9698 95 "(j" 9699 94 - l 9696 t-676, 90 0 L-676, 89700604 87 0-71 0.05 3 o, 025 3 90085
    59
    73
    0.1
    Continuation of table 3
    100
    "
    Ioc
    18
    72
    69 1137 ;. 2852 -4110. .193 1761. .61) ((“-“ ifjljivtf-X lf 9899999794 99 99 93 4986 j,). 9999999895 99 999335 to X titiKf, 9999 999294 C-076 A2 i - 676, 89396 99 9 -00X03- .0.1 3 0.05 3 83 88 .14 0.025 3 46 1 72 1 cells - Decrease in the number of specimens caused by
    Atiparasitic activity of C-076 in case of slush on artificially infected cattle
    Body type
    f —Significant decrease in efficiency compared to the efficiency with other 1 “1 soedieinein s-76,.
    & -Exterior application.
    Table 5 99, 36 87 46 46 53 О 69 11 5 23 About parasites compared with the control treatment, 05,, 01 0.001, respectively.
    权利要求:
    Claims (3)
    [1]
    1. A method for producing substances possessing anti-parasitic activity, characterized in that the strain Streptomyces aventiitilis NRRZ 8165 (ATTC 31267) is grown in pi-. assimilable carbon and nitrogen sources
    and inorganic salts in aerobic
    conditions with subsequent selection
    from the growing medium of the target product.
    [2]
    2. Method-POP.1, characterized in that the extraction of said strain of a microorganism is carried out at a temperature of 20-40 ° C, the pH of the medium is 6.0-7.5 for 1-8 days ..
    [3]
    3. The method according to claims 1 and 2, which is based on the fact that the microorganism is grown on the medium containing 0.55% of carbon sources and 0.2-6.0% of nitrogen sources.
    4, POP1 method, characterized in that the target product is isolated by filtering the growth medium, followed by extracting the residue on the filter of the mycelium with water-miscible organic solvents, evaporating the organic solvent and extracting the residue with an organic miscible with water.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU716524A3|1980-02-15|Method of preparing substances possessing antiparasitic activity
    US4460765A|1984-07-17|Enzyme inhibitor produced by cultivation of streptomyces microorganisms
    EP0366060B1|1994-03-02|Glycosidase inhibitor salbostatin, method for its production and its use
    DK141761B|1980-06-09|Process for the preparation of antibiotics aclacinomycin A and / or B or salts or deoxyribonucleic acid complexes thereof.
    NL8001982A|1980-10-09|ANTIBIOTIC ACTIVE SUBSTANCE AND METHOD FOR PREPARING AND USING THIS SUBSTANCE AND PHARMACEUTICAL PREPARATION CONTAINING THIS SUBSTANCE.
    JPH0641182A|1994-02-15|Bbm-2, 478b antibiotic
    US4358602A|1982-11-09|Ebelactones and production thereof
    HU188684B|1986-05-28|Process for producing a2, and simultaneously produced a1 and a3 components of antibioticum a/16686
    EP0185456B1|1990-11-07|Cl-1577d and cl-1577e antibiotic/antitumor compounds, their production and use
    JP2802097B2|1998-09-21|Novel anticancer antibiotic MI43-37F11 and method for producing the same
    AT395860B|1993-03-25|METHOD FOR PRODUCING A NEW ANTITUMOR ANTIBIOTIC AND ITS USE
    SU867318A3|1981-09-23|Method of preparing baumycin a and b
    EP0345735A2|1989-12-13|Glycoside antibiotics BU-3608D and BU-3608E
    EP0194784A2|1986-09-17|CL-1577-B4 Compound, its production and use
    US4792522A|1988-12-20|Rigolettone antitumor complex
    DE2833689C2|1987-08-20|
    CH626628A5|1981-11-30|Process for the preparation of an antibiotic
    DE60004669T2|2004-07-08|INDOLOCARBAZOLAL CALOIDS FROM A NAVY ACTINOMYCETE
    RU2134694C1|1999-08-20|Aminooligosaccharide &#34;sk-4416&#34;, method of its synthesis, inhibitor of saccharide hydrolase and antibacterial agent
    CA1046965A|1979-01-23|Naphthyridinomycin antibiotics from streptomyces
    JP3107455B2|2000-11-06|New antibiotic MI481-42F4-A and method for producing the same
    FR2547594A1|1984-12-21|NOVEL ANTITUMOR ANTIBIOTIC COMPLEXES AND PROCESS FOR THE CULTURAL PRODUCTION OF ACTINOMADURA VERRUCOSOSPORA STRAIN
    SU618053A3|1978-07-30|Method of obtaining antibacterial substance
    EP0050964B1|1987-03-04|Macrocyclic lactones, their production and parasiticidal uses, compositions containing them, and a biological culture suitable for producing them
    JP3192723B2|2001-07-30|Novel macrolide antibiotics SF2748B, SF2748C1, SF2748D and SF2748E and their production
    同族专利:
    公开号 | 公开日
    JPS52151197A|1977-12-15|
    ATA266277A|1979-12-15|
    DK146514C|1984-04-09|
    NL188859C|1992-10-16|
    CY1114A|1981-12-04|
    GB1573955A|1980-08-28|
    FI57781C|1980-10-10|
    MY8200087A|1982-12-31|
    IL51854D0|1977-06-30|
    NO148856B|1983-09-19|
    IE44822B1|1982-04-07|
    SE7703592L|1977-10-20|
    DD137727A5|1979-09-19|
    FR2348970B1|1980-04-25|
    FR2348970A1|1977-11-18|
    BG35900A3|1984-07-16|
    DE2717040A1|1977-11-10|
    PL108004B1|1980-03-31|
    YU40814B|1986-06-30|
    AU513641B2|1980-12-11|
    BE853702A|1977-10-18|
    NL950005I1|1995-06-16|
    ES457932A1|1978-06-01|
    DE2717040C2|1986-09-18|
    JPH0217558B2|1990-04-20|
    NL971001I2|1997-08-01|
    OA05638A|1981-04-30|
    FI771124A|1977-10-20|
    RO71785A|1982-10-26|
    NL971001I1|1997-06-02|
    IE44822L|1977-10-19|
    NZ183847A|1980-05-08|
    DK149077A|1977-10-20|
    NO148856C|1983-12-28|
    CA1098063A|1981-03-24|
    GT197746150A|1978-10-10|
    NO771211L|1977-10-20|
    KE3141A|1981-07-24|
    CS207397B2|1981-07-31|
    LU77152A1|1977-11-17|
    SE434277B|1984-07-16|
    AT357503B|1980-07-10|
    HU179041B|1982-08-28|
    AR215000A1|1979-08-31|
    DK146514B|1983-10-24|
    HK38481A|1981-08-07|
    GR63128B|1979-09-17|
    PT66445A|1977-05-01|
    IT1106424B|1985-11-11|
    IL51854A|1980-03-31|
    ZM3677A1|1978-08-21|
    US4310519A|1982-01-12|
    CH639422A5|1983-11-15|
    PT66445B|1979-03-09|
    ZA772345B|1978-12-27|
    FI57781B|1980-06-30|
    NL950005I2|1997-02-03|
    NL188859B|1992-05-18|
    NL7703810A|1977-10-21|
    AU2422077A|1978-10-19|
    YU100177A|1983-02-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JPS4914624A|1972-06-08|1974-02-08|
    US3950360A|1972-06-08|1976-04-13|Sankyo Company Limited|Antibiotic substances|
    US4134973A|1977-04-11|1979-01-16|Merck & Co., Inc.|Carbohydrate derivatives of milbemycin and processes therefor|
    US4160083A|1977-10-03|1979-07-03|Merck & Co., Inc.|Process for the separation of antibiotic macrolides|
    US4160861A|1977-10-03|1979-07-10|Merck & Co., Inc.|Method for the separation of antibiotic macrolides|
    US4161583A|1977-10-03|1979-07-17|Merck & Co., Inc.|Method for the separation and purification of antibiotic macrolides|
    US4160084A|1977-10-11|1979-07-03|Merck & Co., Inc.|Method for the separation of antibiotic macrolides|NZ186851A|1977-04-11|1984-12-14|Merck & Co Inc|Glycosyloxy derivatives of milbemycin and parasiticidal compositions|
    US4093629A|1977-04-11|1978-06-06|Merck & Co., Inc.|Derivatives of antibiotic substance milbemycin and processes therefor|
    NZ188459A|1977-10-03|1982-09-07|Merck & Co Inc|Derivatives of c-076 compounds and pesticidal compositions|
    PH15982A|1977-10-03|1983-05-18|Merck & Co Inc|Selective hydrogenation producta of c-076 compounds and derivatives thereof|
    US4206205A|1977-10-03|1980-06-03|Merck & Co., Inc.|Monosaccharide and aglycone derivatives of C-076|
    PH16612A|1977-12-19|1983-11-28|Merck & Co Inc|13-halo and 13-deoxy derivatives of c-076 compounds|
    US4203976A|1978-08-02|1980-05-20|Merck & Co., Inc.|Sugar derivatives of C-076 compounds|
    US4200581A|1978-08-04|1980-04-29|Merck & Co., Inc.|Alkyl derivatives of C-076 compounds|
    US4263168A|1979-01-10|1981-04-21|Imperial Chemical Industries Limited|Olefine polymerization catalyst|
    US4550160A|1979-08-13|1985-10-29|Merck & Co., Inc.|Processes for the interconversion of C-076 compounds|
    JPH0217555B2|1979-08-23|1990-04-20|Sankyo Co|
    US4289760A|1980-05-02|1981-09-15|Merck & Co., Inc.|23-Keto derivatives of C-076 compounds|
    US4285963A|1980-08-07|1981-08-25|Merck & Co., Inc.|Novel derivatives of C-076 compounds|
    US4385065A|1980-10-23|1983-05-24|Merck & Co., Inc.|Novel substances and process for their production|
    US4378353A|1981-02-17|1983-03-29|Merck & Co., Inc.|Novel C-076 compounds|
    US4333925A|1981-05-11|1982-06-08|Merck & Co., Inc.|Derivatives of C-076 compounds|
    US4399274A|1981-07-02|1983-08-16|Merck & Co., Inc.|Isolation of non-ionic lipophilic materials on macroreticular polymeric absorbents|
    US4412991A|1981-08-28|1983-11-01|Merck & Co., Inc.|22-Hydroxy derivatives of C-076 compounds, pharmaceutical compositions and method of use|
    NZ201681A|1981-09-03|1985-11-08|Merck & Co Inc|Avermectin derivatives and parasiticidal compositions|
    US4457920A|1981-09-03|1984-07-03|Merck & Co., Inc.|4a-Substituted avermectin compounds|
    US4423211A|1981-12-21|1983-12-27|Merck & Co., Inc.|Process for the whole broth extraction of avermectin|
    US4423209A|1982-02-26|1983-12-27|Merck & Co., Inc.|Processes for the interconversion of avermectin compounds|
    US4427663A|1982-03-16|1984-01-24|Merck & Co., Inc.|4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof|
    NZ204074A|1982-05-10|1986-05-09|Merck & Co Inc|Synergistic compositions containing avermectins|
    US4430329A|1982-05-17|1984-02-07|Merck & Co., Inc.|Synergistic treatment of adult canine heartworm with thiacetarsamide and ivermectin|
    DE3372693D1|1982-07-22|1987-09-03|Ici Plc|Methods and compositions of combating pests|
    US4469682A|1983-01-28|1984-09-04|Merck & Co., Inc.|Avermectin and milbemycin phosphate esters, pharmaceutical compositions, and method of use|
    EP0125155A1|1983-04-07|1984-11-14|Merck & Co. Inc.|Novel synergistic agricultural insecticidal, pesticidal and acaricidal combinations|
    NZ207655A|1983-04-07|1986-09-10|Merck & Co Inc|Synergistic veterinary compositions containing an avermectin compound and clorsulon|
    US4530921A|1983-10-03|1985-07-23|Merck & Co., Inc.|Avermectin epoxide derivatives and method of use|
    US4560677A|1984-01-31|1985-12-24|Merck & Co., Inc.|Synergistic avermectin combination for treating plant pests|
    US5169956A|1984-06-05|1992-12-08|American Cyanamid Company|Macrolide antibiotic compounds|
    US4579864A|1984-06-11|1986-04-01|Merck & Co., Inc.|Avermectin and milbemycin 13-keto, 13-imino and 13-amino derivatives|
    US5182207A|1984-09-14|1993-01-26|American Cyanamid Company|Strains of streptomyces thermoarchaensis|
    PL152148B1|1984-09-14|1990-11-30|Glaxo Group Ltd|Antibiotic compounds and their preparation|
    US4587247A|1985-02-25|1986-05-06|Merck & Co., Inc.|Substituted and unsubstituted 13-methoxy derivatives of the avermectin aglycones, compositions and use|
    US4666937A|1985-03-04|1987-05-19|Merck & Co., Inc.|Avermectin bioconversion products|
    NZ215917A|1985-05-02|1989-10-27|Merck & Co Inc|22-oh milbemycin derivatives and parasiticidal compositions|
    US4789684A|1985-05-02|1988-12-06|Merck & Co., Inc.|Anthelmintic fermentation products of microorganisms|
    US4678774A|1985-06-06|1987-07-07|Merck & Co., Inc.|Novel synergistic compositions|
    ES8800986A1|1985-07-27|1987-12-01|Pfizer|Antiparasitic avermectin and milbemycin derivatives and process for their preparation.|
    US5840704A|1986-07-16|1998-11-24|Pfizer Inc.|Antiparasitic agents and process for their preparation|
    US4766112A|1985-07-29|1988-08-23|Merck & Co. Inc.|Anthelmintic fermentation products of a microorganism|
    US4668696A|1985-07-29|1987-05-26|Merck & Co., Inc.|Novel averonectin fermentation product of a microorganism with anthelmintic activity|
    NZ216908A|1985-07-29|1989-06-28|Merck & Co Inc|Avermectin derivatives|
    US4622313A|1985-08-01|1986-11-11|Merck & Co., Inc.|O-sulfate derivatives of avermectins and milbemycins having improved water solubility|
    ES8605582A1|1985-12-11|1986-03-16|Antibioticos Sa|Production of avermectins|
    GB8606116D0|1986-03-12|1986-04-16|Glaxo Group Ltd|Process|
    GB8606120D0|1986-03-12|1986-04-16|Glaxo Group Ltd|Process|
    EP0240274A3|1986-04-03|1990-03-14|Merck & Co. Inc.|Avermectins as growth promotant agents|
    JP2587241B2|1986-07-24|1997-03-05|ビ−チヤム・グル−プ・ピ−エルシ−|Novel compound, production method thereof and pharmaceutical composition containing the same|
    US4833168A|1986-10-03|1989-05-23|Merck & Co., Inc.|Avermectin reformatsky adducts|
    US5077398A|1986-11-18|1991-12-31|Merck & Co., Inc.|Process for isolation of avermectin B1 components with improved purity and subsequent isolaton of B2 components|
    US5234831A|1987-01-23|1993-08-10|Pfizer Inc|Cultures for production of B avermectins|
    US5238848A|1987-01-23|1993-08-24|Pfizer Inc|Cultures for production of avermectins|
    US5525506A|1987-01-23|1996-06-11|Pfizer Inc.|Process for production of avermectins and cultures therefor|
    IL85119A|1987-01-23|1993-01-14|Pfizer|Streptomyces avermitilis strains, their preparation and use in production of avermectins|
    IN167980B|1987-01-23|1991-01-19|Pfizer|
    US5077278A|1987-01-23|1991-12-31|Pfizer Inc.|Non-natural demethylavermectins compositions and method of use|
    US4806527A|1987-03-16|1989-02-21|Merck & Co., Inc.|Avermectin derivatives|
    US4831017A|1987-06-29|1989-05-16|Merck & Co., Inc.|Increased litter size in monogastric domestic animals after treatment in mid-gestation of gravid female with avermectin or milbemycin compound|
    US4847243A|1987-10-08|1989-07-11|Merck & Co., Inc.|Treatment for fescue toxicosis in grazing animals|
    ES2054822T3|1987-10-23|1994-08-16|Pfizer|PROCEDURE FOR THE PRODUCTION OF AVERMECTIN AGLICONES AND THEIR CROPS.|
    US5240850A|1987-10-23|1993-08-31|Pfizer Inc.|Cultures for production of avermectin aglycones|
    CA1340771C|1987-11-09|1999-09-28|Shih-Jen Edward Lee|Ethylated avermectins|
    US4963667A|1987-11-10|1990-10-16|Merck & Co., Inc.|Ivermectin derivative compounds and process for preparing the same|
    GB8726730D0|1987-11-14|1987-12-16|Pfizer Ltd|Antiparasitic agents|
    US4895837A|1988-01-29|1990-01-23|Merck & Co., Inc.|Avermectin derivatives|
    GB8804440D0|1988-02-25|1988-03-23|Pfizer Ltd|Antiparasitic agents|
    US4918097A|1988-03-11|1990-04-17|Ciba-Geigy Corporation|Insecticides and parasiticides|
    GB8815967D0|1988-07-05|1988-08-10|Pfizer Ltd|Antiparasitic agents|
    US5015662A|1988-10-18|1991-05-14|Merck & Co., Inc.|Anthelmintic bioconversion products|
    US5120646A|1988-10-18|1992-06-09|Chen Shieh Shung T|Process for the preparation of anthelmintive bioconversion products|
    US5015630A|1989-01-19|1991-05-14|Merck & Co., Inc.|5-oxime avermectin derivatives|
    US4897383A|1989-02-13|1990-01-30|Merck & Co., Inc.|Avermectin derivatives|
    NZ232422A|1989-02-16|1992-11-25|Merck & Co Inc|13-ketal milbemycin derivatives and parasiticides|
    AT129286T|1989-03-31|1995-11-15|Merck & Co Inc|CLONING OF STREPTOMYCES AVERMITILIS GENES FOR THE BIOSYNTHESIS OF AVERMECTIN AND METHOD FOR THE USE THEREOF.|
    US5030622A|1989-06-02|1991-07-09|Merck & Co., Inc.|Avermectin derivatives|
    US5023241A|1989-07-31|1991-06-11|Merck & Co., Inc.|Avermectin derivatives|
    US5055454A|1989-10-30|1991-10-08|Merck & Co., Inc.|13-epi-avermectin derivatives useful as antiparasitic agents|
    US5830875A|1989-10-30|1998-11-03|Merck & Co., Inc.|24-and 25-substituted avermectin and milbemycin derivatives|
    JP2888586B2|1990-03-05|1999-05-10|社団法人北里研究所|Microorganism for selective production of specific components of avermectin and its selective production method|
    US5114930A|1990-05-14|1992-05-19|Merck & Co., Inc.|Avermectin derivatives with a spacer inserted between the disaccharide and the aglycone useful as antiparasitic agents|
    US5188944A|1990-06-22|1993-02-23|Merck & Co., Inc.|Process for the glycosylation of avermectin agylcones|
    US5070015A|1990-10-15|1991-12-03|Merck & Co., Inc.|Novel avermectins are produced from known microorganisms|
    US5346698A|1991-01-15|1994-09-13|Mycogen Corporation|Synergistic pesticidal compositions|
    US5192546A|1991-01-15|1993-03-09|Mycogen Corporation|Synergistic pesticidal compositions|
    US5177063A|1991-03-11|1993-01-05|Merck & Co., Inc.|Avermectin compounds with a 6,5-spiroketal ring system|
    US5208222A|1991-03-28|1993-05-04|Merck & Co., Inc.|4"-and 4'-alkylthio avermectin derivatives|
    US5189026A|1991-06-07|1993-02-23|Fractal Laboratories, Inc.|Treatment of human diseases involving dysregulation or dysfunction of the nervous system|
    US5262400A|1991-06-20|1993-11-16|Merck & Co., Inc.|4α-substituted avermectin derivatives|
    US5192671A|1991-06-26|1993-03-09|Merck & Co., Inc.|Process for the glycosylation of avermectin compounds|
    EP0524687A1|1991-07-23|1993-01-27|Merck & Co. Inc.|A process for the glycosylation of avermectin compounds at the 14a-position|
    EP0524686A1|1991-07-23|1993-01-27|Merck & Co. Inc.|A process for the 14a-hydroxylation of avermectin compounds|
    US5240915A|1991-10-15|1993-08-31|Merck & Co., Inc.|Avermectin derivatives|
    US5171742A|1991-10-15|1992-12-15|Merck & Co., Inc.|Avermectin compounds with a 6,5-spiroketal ring system ad a 23-acyl substituent|
    US5248669A|1991-12-17|1993-09-28|Samir Amer|Inhibition of anoxia or hypoxia-induced, endothelium-mediated vasospasm with avermectins|
    GB9205007D0|1992-03-07|1992-04-22|Pfizer Ltd|Antiparasitic agents|
    US5162363A|1992-03-18|1992-11-10|Merck & Co., Inc.|23-nor-23-thia avermectin analogs are active anthelmintic agents|
    US5244879A|1992-03-18|1993-09-14|Merck & Co., Inc.|23-nor-23-oxa avermectin analogs are active anthelmintic agents|
    US5312753A|1992-03-23|1994-05-17|Merck & Co., Inc.|Strain of streptomyces avermitilis capable of glycosylating avermectin compounds at the 13- and 14A positions|
    DE69329821T2|1992-03-23|2001-07-19|Merck & Co Inc|A STREPTOMYCES AVERMITILIS STRAG GLYCOSYLATES AVERMECTIN COMPOUNDS|
    US5229415A|1992-03-24|1993-07-20|Merck & Co., Inc.|Alkylthio alkyl avermectins are active antiparasitic agents|
    US6103504A|1992-03-25|2000-08-15|Pfizer Inc.|Process for production of avermectins and cultures therefor|
    IT1255135B|1992-05-05|1995-10-20|ACTIVE INGREDIENT BASED ON AVERMECTINE, STRAW AND PROCEDURE FOR ITS PREPARATION AND VETERINARY COMPOSITION THAT CONTAINS IT.|
    US5248678A|1992-06-30|1993-09-28|Fractal Laboratories, Inc.|Methods for increasing arousal and alertness and for the amelioration of comatose states|
    US5241083A|1992-07-01|1993-08-31|Merck & Co., Inc.|Process for converting the 13-α-hydroxy group of avermectin aglycones|
    US6162825A|1992-10-22|2000-12-19|The Clorox Company|High fructose insecticide bait compositions|
    US5547955A|1992-10-22|1996-08-20|The Clorox Company|High fructose insecticide bait compositions|
    US5292647A|1992-11-30|1994-03-08|Eli Lilly And Company|Strain of streptomyces for producing avermectins and processes therewith|
    US5411946A|1993-02-24|1995-05-02|Merck & Co., Inc.|Avermectin derivatives|
    US5602107A|1993-05-10|1997-02-11|Merck & Co., Inc.|Pour-on formulations consisting of gylcols, glycerides and avermectin compounds|
    PL174488B1|1993-05-10|1998-08-31|Merck & Co Inc|Preparations for fighting against animal parasites and method of obtaining such preparations|
    DE69415675T2|1993-07-23|1999-05-20|Pfizer|Process for the precipitation of natural avermectins and fermentation process for the production of the same|
    US5478929A|1993-09-15|1995-12-26|Merck & Co., Inc.|Bioconversion products of 27-hydroxy avermectin|
    US5380838A|1993-10-08|1995-01-10|Merck & Co. Inc.|Stable solvates of avermectin compounds|
    US5399582A|1993-11-01|1995-03-21|Merck & Co., Inc.|Antiparasitic agents|
    TW327125B|1994-02-07|1998-02-21|Merck & Co Inc|Composition and method for protecting against pine exhausted|
    US5578581A|1994-04-26|1996-11-26|Merck & Co., Inc.|Active avermectin analogue|
    US5550153A|1994-11-14|1996-08-27|Kerz; Phillip D.|Method for treating heartworm-infected canines|
    BR9607262A|1995-02-24|1997-12-30|Norvatis Ag Novartis Sa Novart|Composition to control parasites|
    MX9707216A|1995-03-20|1997-11-29|Merck & Co Inc|Nodulisporic acid derivatives.|
    DE19520275A1|1995-06-02|1996-12-05|Bayer Ag|Endoparasiticidal agents|
    US5674897A|1995-10-20|1997-10-07|Mycogen Corporation|Materials and methods for controlling nematodes|
    US6124359A|1995-10-20|2000-09-26|Mycogen Corporation|Materials and methods for killing nematodes and nematode eggs|
    DE19613972A1|1996-04-09|1997-10-16|Bayer Ag|Injection formulations of avermectins and milbemycins based on castor oil|
    AUPN933396A0|1996-04-17|1996-05-09|Pfizer Pty Limited|Non-aqueuos oral-drench compositions containing avermectin compounds|
    EP0928136B1|1996-06-05|2003-10-22|Ashmont Holdings Limited|Injectable compositions|
    US6403308B1|1997-04-30|2002-06-11|Mcgill University|Methods for detecting and reversing resistance to macrocyclic lactone compounds|
    US6114376A|1997-04-30|2000-09-05|Mcgill University|Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells|
    PL192651B1|1997-12-03|2006-11-30|Merck & Co Inc|Prolonged action injectable preparations containing hydrogenated castor oil|
    KR20040053390A|1998-02-13|2004-06-23|화이자 프로덕츠 인코포레이티드|Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins|
    US6733767B2|1998-03-19|2004-05-11|Merck & Co., Inc.|Liquid polymeric compositions for controlled release of bioactive substances|
    GB9825402D0|1998-11-19|1999-01-13|Pfizer Ltd|Antiparasitic formulations|
    GB9926887D0|1999-11-12|2000-01-12|Novartis Ag|Organic compounds|
    US6787342B2|2000-02-16|2004-09-07|Merial Limited|Paste formulations|
    DE10013914A1|2000-03-21|2001-09-27|Bayer Ag|Synergistic pesticidal composition comprising 4-hydroxy-3-phenyl-furan-2-one derivative and bifenazate, abamectin or bifenthrin, are useful as insecticide, acaricide, ectoparasiticide or antifouling agents|
    US7897559B2|2000-06-29|2011-03-01|Parks L Dean|Dermatological composition and kit containing avermectin compound for treating dermatological conditions|
    US6399651B1|2000-06-29|2002-06-04|L. Dean Parks|Method of treating dermatoses using avermectin compound|
    DE10055941A1|2000-11-10|2002-05-23|Bayer Ag|Pesticidal agent containing mixture of aryl-substituted pyrrolidine enol ethers and known insecticides or acaricides|
    DE10059606A1|2000-12-01|2002-06-06|Bayer Ag|drug combinations|
    AR036872A1|2001-08-13|2004-10-13|Du Pont|ANTRANILAMIDE COMPOSITE, COMPOSITION THAT INCLUDES IT AND METHOD FOR CONTROLLING AN INVERTEBRATE PEST|
    DE10203688A1|2002-01-31|2003-08-07|Bayer Cropscience Ag|Synergistic insecticidal mixtures|
    WO2003068955A2|2002-02-12|2003-08-21|Pfizer Products Inc.|Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins|
    DE10207241A1|2002-02-21|2003-09-04|Bayer Cropscience Ag|Synergistic insecticidal mixtures|
    GB2386066A|2002-02-28|2003-09-10|Norbrook Lab Ltd|Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species|
    US20080027011A1|2005-12-20|2008-01-31|Hassan Nached|Homogeneous paste and gel formulations|
    US7001889B2|2002-06-21|2006-02-21|Merial Limited|Anthelmintic oral homogeneous veterinary pastes|
    US20060205681A1|2002-06-21|2006-09-14|Maryam Moaddeb|Homogenous paste formulations|
    US6764999B2|2002-07-11|2004-07-20|Stephen E. Bachman|Nasal delivery of parasiticides|
    US20040077703A1|2002-10-02|2004-04-22|Soll Mark D.|Nodulisporic acid derivative spot-on formulations for combating parasites|
    DE10248257A1|2002-10-16|2004-04-29|Bayer Cropscience Ag|Active ingredient combinations in insecticidal and acaricidal properties|
    GB0229804D0|2002-12-20|2003-01-29|Syngenta Participations Ag|Avermection b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substituent in the 4"- or 4'-position|
    GB0316377D0|2003-07-12|2003-08-13|Norbrook Lab Ltd|Parasiticidal composition|
    DE10353281A1|2003-11-14|2005-06-16|Bayer Cropscience Ag|Combination of active ingredients with insecticidal and acaricidal properties|
    US7531186B2|2003-12-17|2009-05-12|Merial Limited|Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz|
    US7671034B2|2003-12-19|2010-03-02|Merial Limited|Stabilized formulation of ivermectin feed premix with an extended shelf life|
    US7666444B2|2004-02-02|2010-02-23|Wyeth|Antiparasitic composition|
    US7493609B2|2004-08-30|2009-02-17|International Business Machines Corporation|Method and apparatus for automatic second-order predictive commoning|
    CA2580843C|2004-09-23|2011-03-29|Schering-Plough Ltd.|Control of parasites in animals by the use of trifluoromethanesulfonanilide oxime ether derivatives|
    DE102004053964A1|2004-11-09|2006-05-11|Bayer Healthcare Ag|Remedy for demodicosis|
    AT446677T|2004-11-19|2009-11-15|Schering Plough Ltd|CONTROL OF PARASITES IN ANIMALS BY USING PARASITICIDES 2-PHENYL-3-ACRYLONITRILE DERIVATIVES|
    GB0501220D0|2005-01-21|2005-03-02|Norbrook Lab Ltd|Anthelmintic composition|
    US8362086B2|2005-08-19|2013-01-29|Merial Limited|Long acting injectable formulations|
    US8119667B2|2005-12-29|2012-02-21|Schering-Plough Animal Health Corporation|Carbonates of fenicol antibiotics|
    EP1849363A1|2006-03-09|2007-10-31|Cheminova A/S|Synergistic combination of glutamate- and GABA-gated chloride agonist pesticide and at least one of Vitamin E or Niacin|
    US20070238700A1|2006-04-10|2007-10-11|Winzenberg Kevin N|N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites|
    TWI422328B|2006-06-19|2014-01-11|Univ California|Combinations of biological control agents with a nematicidal seed coating|
    DK2035390T3|2006-07-05|2016-01-04|Merial Inc|1-aryl-5-alkylpyrazolderivatforbindelser, methods of making and methods of use thereof|
    DE102007007750A1|2006-08-17|2008-02-21|Bayer Cropscience Ag|avermectin derivatives|
    FR2906468B1|2006-09-28|2012-09-21|Galderma Sa|USE OF COMPOUNDS OF THE AVERMECTIN FAMILY FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS|
    CN101605756A|2006-12-13|2009-12-16|先灵-普劳有限公司|The water-soluble prodrug of florfenicol and analogue thereof|
    CN101600686A|2006-12-13|2009-12-09|先灵-普劳有限公司|The water-soluble prodrug of paraxin, thiamphenicol and analogue thereof|
    US8901163B2|2007-01-03|2014-12-02|Galderma S.A.|Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound|
    HUE042633T2|2007-05-15|2019-07-29|Merial Inc|Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof|
    TWI430995B|2007-06-26|2014-03-21|Du Pont|Naphthalene isoxazoline invertebrate pest control agents|
    SI2957284T1|2007-06-27|2018-04-30|E.I. Du Pont De Nemours And Company|Animal pest control method|
    BRPI0702873A2|2007-06-29|2011-03-15|Y Tex Corp|pesticide earring|
    US8425925B2|2007-06-29|2013-04-23|Y-Tex Corporation|Pesticidal tag|
    EP2008517A1|2007-06-29|2008-12-31|Bayer CropScience AG|Acaricide active agent combinations|
    TWI556741B|2007-08-17|2016-11-11|英特威特國際股份有限公司|Isoxazoline compositions and their use as antiparasitics|
    EP2039248A1|2007-09-21|2009-03-25|Bayer CropScience AG|Active agent combinations with insecticide and acaricide properties|
    DE102007045922A1|2007-09-26|2009-04-02|Bayer Cropscience Ag|Drug combinations with insecticidal and acaricidal properties|
    MX2010005685A|2007-11-26|2010-09-28|Merial Ltd|Solvent systems for pour-on formulations for combating parasites.|
    US20110028495A1|2007-12-21|2011-02-03|Ernst Baumann|THE USE OF 6-HALOGENO-[1,2,4]-TRIAZOLO-[1,5-a]-PYRIMIDINE COMPOUNDS FOR COMBATING PESTS IN AND ON ANIMALS|
    TWI401023B|2008-02-06|2013-07-11|Du Pont|Mesoionic pesticides|
    EP2127522A1|2008-05-29|2009-12-02|Bayer CropScience AG|Active-agent combinations with insecticidal and acaricidal properties|
    WO2010008891A2|2008-06-24|2010-01-21|Merial Limited|Anthelminthic formulations|
    CA2732017A1|2008-07-30|2010-02-04|Intervet International B.V.|Process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol|
    US20100120652A1|2008-08-08|2010-05-13|Corrado Michael L|Treatment of bed mite and bed bug infestations|
    PT3050874T|2008-11-14|2019-05-09|Boehringer Ingelheim Animal Health Usa Inc|Enantiomerially enriched aryloazol-2-yl cyanoethylamino paraciticidal compounds|
    US8683346B2|2008-11-17|2014-03-25|Sap Portals Israel Ltd.|Client integration of information from a supplemental server into a portal|
    KR101660068B1|2008-11-19|2016-09-26|메리얼 인코포레이티드|Compositions comprising 1-arylpyrazole alone or in combination with formamidine for the treatment of parasitic infection|
    US9173728B2|2008-11-19|2015-11-03|Merial Inc.|Multi-cavity container having offset indentures for dispensing fluids|
    EA019126B1|2008-12-04|2014-01-30|Мериал Лимитед|Dimeric avermectin and milbemycin derivatives|
    EP2227951A1|2009-01-23|2010-09-15|Bayer CropScience AG|Application of enaminocarbonyl compounds for combating viruses transmitted by insects|
    CA2755753A1|2009-03-17|2010-09-23|Intervet International B.V.|Macrocyclic lactone drug delivery system|
    ES2585816T3|2009-03-25|2016-10-10|Bayer Cropscience Ag|Combinations of nematicidal active ingredients comprising fluopiram and Bacillus firmus|
    US9133209B2|2009-07-30|2015-09-15|Merial, Inc.|Insecticidal 4-amino-thieno[2,3-D]-pyrimidine compounds and methods of their use|
    IN2012DN00709A|2009-08-05|2015-06-19|Du Pont|
    TWI508658B|2009-08-05|2015-11-21|Du Pont|Mixtures of mesoionic pesticides|
    TWI489944B|2009-08-05|2015-07-01|Du Pont|Mesoionic pesticides|
    JP2013501063A|2009-08-05|2013-01-10|イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー|Mesoionic insecticide|
    AU2010303741A1|2009-10-07|2012-04-19|Zoetis W Llc|Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof|
    EP2327410A1|2009-10-28|2011-06-01|Consiglio Nazionale Delle Ricerche - Infm Istituto Nazionale Per La Fisica Della Materia|Avermectins and milbemycins for the treatment of flavivirus infections|
    BR112012013482B1|2009-12-04|2018-11-06|Basf Se|bis-organosulfuric compounds pesticides|
    PL3560923T3|2009-12-17|2021-12-27|Boehringer Ingelheim Animal Health USA Inc.|Anti parasitic dihydroazole compounds and compositions comprising same|
    AU2010330844B2|2009-12-17|2014-11-27|Boehringer Ingelheim Animal Health USA Inc.|Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles|
    RS55986B1|2010-01-22|2017-09-29|Bayer Ip Gmbh|Acaricides and/or insecticidal agent combinations|
    UY33282A|2010-03-25|2011-09-30|Novartis Ag|ENDOPARASITICIDE COMPOSITIONS|
    PL2552201T3|2010-04-02|2017-06-30|Merial, Inc.|Parasiticidal compositions comprising multiple active agents, methods and uses thereof|
    EP2382865A1|2010-04-28|2011-11-02|Bayer CropScience AG|Synergistic active agent compounds|
    PL2568980T3|2010-05-12|2016-05-31|Merial Inc|Injectable parasiticidal formulations of levamisole and macrocyclic lactones|
    UY33397A|2010-05-27|2011-12-01|Du Pont|SOLID FORM OF A CARBOXAMIDE NAFTALEN|
    AR081970A1|2010-06-24|2012-10-31|Intervet Int Bv|INJECTABLE FORMULATION OF A MACROCICLIC AND LEVAMISOL LACTONE, FORMULATION AND VETERINARY USE|
    WO2012001083A2|2010-06-29|2012-01-05|Ceva Sante Animale Sa|Novel eprinomectin injectable compositions|
    US8901090B2|2010-10-20|2014-12-02|Galderma S.A.|Method of treating otitis externa using macrocyclic lactone compound|
    EP2629772B1|2010-10-20|2016-05-18|Galderma S.A.|Ivermectin for use in the treatment of hemorrhoids|
    WO2012068202A1|2010-11-16|2012-05-24|Merial Limited|Novel monensin derivatives for the treatment and prevention of protozoal infections|
    WO2012078605A1|2010-12-07|2012-06-14|Merial Limited|Topical combination formulations of macrocyclic lactones with synthetic pyrethroids|
    WO2012087630A1|2010-12-20|2012-06-28|E.I. Du Pont De Nemours And Company|Pyridine and pyrimidine compounds for controlling invertebrate|
    GB201021836D0|2010-12-21|2011-02-02|Norbrook Lab Ltd|Topical Composition|
    WO2012140207A2|2011-04-15|2012-10-18|Syngenta Participations Ag|Method for controlling nematode pests|
    WO2013003505A1|2011-06-27|2013-01-03|Merial Limited|Amido-pyridyl ether compounds and compositions and their use against parasites|
    WO2013003168A1|2011-06-27|2013-01-03|Merial Limited|Novel insect-repellent coumarin derivatives, syntheses, and methods of use|
    CN102356769A|2011-09-02|2012-02-22|魏振东|Wettable powder pesticide containing organic matters|
    EA038853B1|2011-09-12|2021-10-28|БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК.|Pesticidal compositions comprising an isoxazoline active agent and methods of use thereof|
    US20130079394A1|2011-09-23|2013-03-28|Cnrs |Indirect modeling of new repellent molecules active against insects, acarids, and other arthropods|
    EP2780008B1|2011-11-17|2017-07-05|Merial, Inc.|Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof|
    US8715711B2|2011-12-02|2014-05-06|Merial Limited|Long-acting injectable moxidectin formulations and novel moxidectin crystal forms|
    UA119843C2|2012-02-06|2019-08-27|Меріал, Інк|Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof|
    JO3626B1|2012-02-23|2020-08-27|Merial Inc|Topical compositions comprising fipronil and permethrin and methods of use|
    WO2013158422A1|2012-04-17|2013-10-24|E. I. Du Pont De Nemours And Company|Heterocyclic compounds for controlling invertebrate pests|
    NZ701185A|2012-04-20|2015-08-28|Merial Ltd|Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof|
    EP2922845B1|2012-11-20|2018-06-20|Merial, Inc.|Anthelmintic compounds and compositions and method of using thereof|
    US9585871B2|2013-01-31|2017-03-07|Merial, Inc.|Method for treating and curing leishmaniosis using fexinidazole|
    PE20151726A1|2013-04-12|2015-11-18|Zoetis Services Llc|STABLE VETERINARY FORMULATIONS OF COMBINATION OF MACROCYCLIC LACTONES AND IMIDAZOTHIAZOLES|
    AP2016009184A0|2013-11-01|2016-04-30|Merial Ltd|Antiparisitic and pesticidal isoxazoline compounds|
    EP2886640A1|2013-12-18|2015-06-24|Riga Technical University|Process for isolation of milbemycins A3 and A4|
    BR112016023898A8|2014-04-17|2021-03-30|Basf Se|use of malononitrile compounds to protect animals from parasites|
    AR100530A1|2014-05-19|2016-10-12|Merial Inc|ANTIHELMINE COMPOUNDS|
    EA030459B1|2014-06-19|2018-08-31|Мериал, Инк.|Parasiticidal compositions comprising indole derivatives, methods for preparation and use thereof|
    ES2887302T3|2014-10-31|2021-12-22|Boehringer Ingelheim Animal Health Usa Inc|Parasiticidal compositions comprising fipronil|
    EP3023092A1|2014-11-20|2016-05-25|Ceva Sante Animale|Eprinomectin parenteral compositions|
    UY36570A|2015-02-26|2016-10-31|Merial Inc|INJECTABLE FORMULATIONS OF PROLONGED ACTION THAT INCLUDE AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES OF THE SAME|
    CN108055825B|2015-04-08|2021-03-30|勃林格殷格翰动物保健美国公司|Extended release injectable formulations comprising isoxazoline active agents, methods and uses thereof|
    UY36683A|2015-05-20|2016-12-30|Merial Inc|DEPSIPEPTIDE COMPOUNDS AS ANTHELMINICS|
    EP3303385A2|2015-05-27|2018-04-11|Merial, Inc.|Compositions containing antimicrobial igy antibodies, for treatment and prevention of disorders and diseases caused by oral health compromisingmicroorganisms|
    KR101687973B1|2015-12-08|2016-12-21|주식회사 씨티씨바이오|Method for manufacturing premix for livestock feed using microfilm coating|
    UY37137A|2016-02-24|2017-09-29|Merial Inc|ANTIPARASITARY COMPOUNDS OF ISOXAZOLINE, INJECTABLE FORMULATIONS OF PROLONGED ACTION THAT INCLUDE THEM, METHODS AND USES OF THE SAME|
    RU2630316C1|2016-06-24|2017-09-07|Карина Микаилевна Мирзаева|Preparation for combating with insects-ceratophages|
    WO2018039508A1|2016-08-25|2018-03-01|Merial, Inc.|Method for reducing unwanted effects in parasiticidal treatments|
    CA3036450A1|2016-09-22|2018-03-29|Syngenta Participations Ag|Pesticidal mixtures|
    CA3040278A1|2016-10-14|2018-04-19|Boehringer Ingelheim Animal Health USA Inc.|Pesticidal and parasiticidal vinyl isoxazoline compounds|
    MX2019005628A|2016-11-16|2019-12-18|Boehringer Ingelheim Animal Health Usa Inc|Anthelmintic depsipeptide compounds.|
    WO2019005700A1|2017-06-26|2019-01-03|Merial, Inc.|Dual active parasiticidal granule compositions, methods and uses thereof|
    AU2018318945A1|2017-08-14|2020-03-05|Boehringer Ingelheim Animal Health USA Inc.|Pesticidal and parasiticidal pyrazole-isoxazoline compounds|
    WO2019152808A1|2018-02-01|2019-08-08|Yale University|Compositions and methods for inhibition of nuclear-penetrating antibodies|
    WO2019157241A1|2018-02-08|2019-08-15|Boehringer Ingelheim Animal Health USA Inc.|Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof|
    PE20211275A1|2018-07-09|2021-07-19|Boehringer Ingelheim Animal Health Usa Inc|HETEROCYCLIC ANTIHELMINTIC COMPOUNDS|
    EP3883648A1|2018-11-20|2021-09-29|Boehringer Ingelheim Animal Health USA Inc.|Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof|
    AU2020208145A1|2019-01-16|2021-06-24|Boehringer Ingelheim Animal Health USA Inc.|Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof|
    EP3930684A1|2019-03-01|2022-01-05|Boehringer Ingelheim Animal Health USA Inc.|Injectable clorsulon compositions, methods and uses thereof|
    SG11202109786UA|2019-03-19|2021-10-28|Boehringer Ingelheim Animal Health Usa Inc|Anthelmintic aza-benzothiophene and aza-benzofuran compounds|
    CA3146043A1|2019-07-22|2021-01-28|Intervet International B.V.|Soft chewable veterinary dosage form|
    US20210380591A1|2020-05-29|2021-12-09|Boehringer Ingelheim Animal Health USA Inc.|Anthelmintic heterocyclic compounds|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US67832876A| true| 1976-04-19|1976-04-19|
    [返回顶部]